HIF1A and osteoporosis: This indicates that the anti-osteoporotic effect of raloxifene is associated with the activation of HIF-1α and enhanced osteoblast proliferation, which challenges the findings of Chen et al. Given these conflicting outcomes, the role of the HIF-1α signaling pathway in osteogenic activity during osteoporosis treatment requires further investigation.